Dr. Pierre-Axel Vinot, PharmD, PhD joined SparingVision in early 2019 to develop both clinical and CMC activities of the company and is now in charge of the CMC portfolio of the company. Before SparingVision, Pierre-Axel held several positions in public institutions, academic labs, and biotech companies developing early-stage biotech products from the bench up to Phase II clinical trials. Pierre-Axel holds a PhD in Immunology from Sorbonne University, a PharmD from the University of Paris and completed his Pharmacy residency in Paris with a specialization in biotechnology.